<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="app1table4" position="float"><object-id pub-id-type="doi">10.7554/eLife.38200.023</object-id><label>Appendix 1&#8212;table 4.</label><caption><title>Proportions of genotypic drug resistance rates for different anti-TB drugs (beyond isoniazid and rifampicin resistance) and pre-XDR/XDR-TB classification among 705 MDR-MTBC isolates from Samara (n&#160;=&#160;428) and Karakalpakstan (n&#160;=&#160;277), stratified to three identified major phylogenetic clades within the Beijing genotype/lineage and to other Beijing isolates, and to non-Beijing isolates (mainly lineage 4, Euro-American).</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Group</th><th>S</th><th>E</th><th>Z</th><th>Km</th><th>Am</th><th>Cm</th><th>Fq</th><th>Thio</th><th>PAS</th><th>Pre-XDR <break/>XDR</th></tr></thead><tbody><tr><td>Beijing CAO <break/>(n&#160;=&#160;201)</td><td>201/201 <break/>100.0%</td><td>195/201 <break/>97.0%</td><td>152/201 <break/>75.6%</td><td>97/201 <break/>48.3%</td><td>37/201 <break/>18.4%</td><td>37/201 <break/>18.4%</td><td>6/201 <break/>3.0%</td><td>121/201 <break/>60.2%</td><td>99/201 <break/>49.3%</td><td>100/201 <break/>49.8%</td></tr><tr><td>Beijing clade B (W148) (n&#160;=&#160;103)</td><td>103/103 <break/>100.0%</td><td>83/103 <break/>80.6%</td><td>44/103 <break/>42.7%</td><td>61/103 <break/>59.2%</td><td>18/103 <break/>17.5%</td><td>18/103 <break/>17.5%</td><td>23/103 <break/>22.3%</td><td>75/103 <break/>72.8%</td><td>12/103 <break/>11.7%</td><td>64/103 <break/>62.1%</td></tr><tr><td>Beijing clade A (n&#160;=&#160;187)</td><td>184/187 <break/>98.4%</td><td>183/187 <break/>97.9%</td><td>163/187 <break/>87.2%</td><td>177/187 <break/>94.7%</td><td>0/187 <break/>0.0%</td><td>0/187 <break/>0.0%</td><td>33/187 <break/>17.6%</td><td>180/187 <break/>96.3%</td><td>7/187 <break/>3.7%</td><td>179/187 <break/>95.7%</td></tr><tr><td>Other Beijing (n&#160;=&#160;100)</td><td>91/100 <break/>91.0%</td><td>73/100 <break/>73.0%</td><td>52/100 <break/>52.0%</td><td>39/100 <break/>39.0%</td><td>20/100 <break/>20.0%</td><td>23/100 <break/>23.0%</td><td>14/100 <break/>14.0%</td><td>32/100 <break/>32.0%</td><td>15/100 <break/>15.0%</td><td>45/187 <break/>24.1%</td></tr><tr><td>Non-Beijing (n&#160;=&#160;114)</td><td>69/114 <break/>60.5%</td><td>63/114 <break/>55.3%</td><td>30/114 <break/>26.3%</td><td>39/114 <break/>34.2%</td><td>14/114 <break/>12.3%</td><td>14/114 <break/>12.3%</td><td>3/114 <break/>2.6%</td><td>34/114 <break/>29.8%</td><td>34/114 <break/>29.8%</td><td>40/114 <break/>35.1%</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: S&#160;=&#160;streptomycin, E&#160;=&#160;ethambutol, Z&#160;=&#160;pyrazinamide, Km&#160;=&#160;kanamycin, Am&#160;=&#160;amikacin, Cm&#160;=&#160;Capreomycin, Fq&#160;=&#160;fluoroquinolone, Thio&#160;=&#160;thioamide, PAS&#160;=&#160;para aminosalicylic acid</p></fn></table-wrap-foot></table-wrap>